Item 7.01 - Regulation FD Disclosure.

In June 2017, Sesen Bio, Inc. (the "Company") entered into a Cooperative Research and Development Agreement ("CRADA") with the National Cancer Institute ("NCI") for the development of Vicineum™ in combination with AstraZeneca's immune checkpoint inhibitor durvalumab for the treatment of bacillus Calmette-Guérin ("BCG")-unresponsive non-muscle invasive bladder cancer ("NMIBC"). Vicineum is believed to work via a dual mechanism of action to directly kill cancer cells and activate a local inflammatory process that stimulates T-cells, which then proliferate and destroy the cancer cells. Because of this second mechanism, there may be potential for a synergistic effect when given in combination with checkpoint inhibitors. This hypothesis is being tested by the NCI in a Phase 1 clinical trial in patients with BCG-unresponsive NMIBC to evaluate the safety, efficacy and biological correlates of Vicineum in combination with durvalumab ("NCI Trial").

On September 10, 2021, preliminary results from an interim analysis of 12 patients in the NCI Trial ("Interim Analysis") are being presented by Dr. Sandeep Gurram, a Urologic Oncology Fellow at the NCI and an investigator in the NCI Trial, at a conference hosted by the American Urological Association. Enrollment in the Phase 1 clinical trial is ongoing. A copy of such presentation is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Based on the Interim Analysis, the combination of Vicineum and durvalumab has been generally well-tolerated with no new safety signals emerging (no Grade 4 or 5 treatment-related adverse events) and has a similar safety profile compared to both agents used individually. The Interim Analysis also indicated a 3-month complete response rate of 42% (5/12) and a 12-month complete response rate of 17% (2/12).

The information furnished in this Item 7.01, including the presentation attached as Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements regarding the belief that Vicineum works via a dual mechanism of action that kills cancer cells, the safety, efficacy and tolerability of the combination of Vicineum and durvalumab based on the NCI's Interim Analysis, which are based on the Company's current expectations and inherently involve significant risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that the hypothesis regarding Vicineum's dual mechanism of action may fail after further investigation, the risk that the Interim Analysis may not be predictive of the success of later clinical trials, the Interim Analysis does not necessarily predict final results, clinical data and analyses are often susceptible to varying interpretations, the clinical trial process may fail to demonstrate that the combination of Vicineum and durvalumab is both safe and effective for their intended uses, the combination of Vicineum and durvalumab for the treatment of BCG-unresponsive NMIBC may cause undesirable side effects and serious adverse events or have other properties that could delay or halt clinical trials, among other risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company's most recent annual report on Form 10-K and the Company's quarterly reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in its expectations.




Item 9.01 - Financial Statements and Exhibits.
(d) Exhibits.

--------------------------------------------------------------------------------



Exhibit No.                Description

99.1                         NCI Presentation Made at the 2021 American Urological Association
                           Conference on September 10, 2021
104                        Cover Page Interactive Data File (embedded within the Inline XBRL
                           document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses